clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2025-103-6-420-425clinmed-1168Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСаркопения у пациентов с сахарным диабетом 2-го типаSarcopenia in patients with type 2 diabetes mellitushttps://orcid.org/0000-0002-8689-6623ОбъедковР. Н.ObedkovR. N.

Объедков Руслан Николаевич — ординатор кафедры госпитальной терапии им. акад. Г.И. Сторожакова Института клинической медицины (ИКМ)

Москва

Ruslan N. Obedkov — Resident of the Department of Hospital Therapy named after Academician G.I. Storozhakov of the Institute of Clinical Medicine

Moscow

rn.obedkov98@gmail.comhttps://orcid.org/0000-0002-9118-3708ДедовЕ. И.DedovE. I.

Дедов Евгений Иванович — д-р мед. наук, профессор кафедры госпитальной терапии им. акад. Г.И. Сторожакова ИКМ; врач-ревматолог

Москва

Evgeny I. Dedov — Doctor of Medical Sciences, Professor of the Department of Hospital Therapy named after Academician G.I. Storozhakov; rheumatologist

Moscow

https://orcid.org/0000-0002-7980-5500МодестоваА. В.ModestovaA. V.

Модестова Анна Владимировна — канд. мед. наук, доцент кафедры госпитальной терапии им. акад. Г.И. Сторожакова ИКМ

Москва

Anna V. Modestova — Candidate of Medical Sciences, Associate Professor of the Department of Hospital Therapy named after Academician G.I. Storozhakov of the I nstitute of Clinical Medicine

Moscow

https://orcid.org/0000-0001-8614-6542КокоринВ. А.KokorinV. A.

Кокорин Валентин Александрович — д-р мед. наук, заведующий кафедрой госпитальной терапии с курсами эндокринологии, гематологии и клинической лабораторной диагностики; профессор кафедры госпитальной терапии им. акад. П.Е. Лукомского ИКМ

Москва

Valentin A. Kokorin — Doctor of Medical Sciences, Head of the Department of Hospital Therapy with courses in Endocrinology, Hematology and Clinical Laboratory Diagnostics; Professor of the Department of Hospital Therapy named after Academician P.E. Lukomsky of the Institute of Clinical Medicine

Moscow

ПшенниковаИ. Г.PshennikovaI. G.

Пшенникова Ирина Геннадьевна — врач-эндокринолог, заведующая эндокринологическим отделением

Москва

Irina G. Pshennikova — Endocrinologist

Moscow

ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияN.I. Pirogov Russian National Research Medical UniversityRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ГБУЗ «Городская клиническая больница им. В.М. Буянова» Департамента здравоохранения г. МосквыРоссияN.I. Pirogov Russian National Research Medical University; V.M. Buyanov City Clinical HospitalRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»РоссияN.I. Pirogov Russian National Research Medical University; Peoples' Friendship University of Russia named after Patrice LumumbaRussian FederationГБУЗ «Городская клиническая больница им. В.М. Буянова» Департамента здравоохранения г. МосквыРоссияV.M. Buyanov City Clinical HospitalRussian Federation2025311020251036420425Copyright © Объедков Р.Н., Дедов Е.И., Модестова А.В., Кокорин В.А., Пшенникова И.Г., 20252025Объедков Р.Н., Дедов Е.И., Модестова А.В., Кокорин В.А., Пшенникова И.Г.Obedkov R.N., Dedov E.I., Modestova A.V., Kokorin V.A., Pshennikova I.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/1168

Сахарный диабет и саркопения являются распространенными патологиями среди лиц пожилого и старческого возраста. По мере старения организма происходит постепенное снижение функционирующей мышечной массы, что приводит к развитию саркопении. Учитывая, что мышечная ткань играет немаловажную роль в гомеостазе глюкозы, это обстоятельство непременно сказывается и на течении сахарного диабета. Цель обзора: подробно описать патогенетические взаимодействия двух возраст-ассоциированных заболеваний — саркопении и сахарного диабета 2-го типа. Понимание общности патогенеза даст возможность разобраться в течении обоих заболеваний и определить тактику ведения данных пациентов, что в свою очередь позволит замедлить их прогрессирование, достичь и реализовать концепцию активного, здорового старения, продлить период высокой физической, а также функциональной активности.

Diabetes mellitus, as well as sarcopenia, are a common pathology among the elderly and senile. As the body ages, there is a gradual decrease in functioning muscle mass, which leads to the development of sarcopenia, given that muscle plays an important role in glucose homeostasis, this circumstance certainly affects the course of diabetes mellitus. The purpose of the review was to describe in detail the pathogenetic interactions of two age-related diseases sarcopenia and type 2 diabetes mellitus. Understanding the common pathogenesis will make it possible to understand the course of both diseases and determine the tactics of managing these patients. This, in turn, will slow down their progression, achieve and implement the concept of active, healthy aging, and prolong the period of high physical as well as functional activity.

сахарный диабетсаркопениямышечная слабостьинсулинорезистентностьвоспалениеокислительный стрессвнутримышечная жировая тканьdiabetes mellitussarcopeniamuscle weaknessinsulin resistanceinflammationoxidative stressintramuscular adipose tissueReferencesАлгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. М. 2023 DOI: 10.14341/DM13042Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I.I. Dedov, M.V. Shestakova, A.Y. Mayorov. 11th edition. M. 2023. (In Russian). DOI: 10.14341/DM13042Шестакова М.В., Викулова О.К., Железнякова А.В. и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019;91(10):4–13. DOI: 10.26442/00403660.2019.10.000364Shestakova M.V., Vikulova O.K., Zheleznyakova A.V. and others. Epidemiology of diabetes mellitus in the Russian Federation: What has changed in the last decade? Therapeutic Archive. 2019;91(10):4–13. (In Russian). DOI: 10.26442/00403660.2019.10.000364Izzo A., Massimino E., Riccardi G. et al. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients. 2021;13(1):183. DOI: 10.3390/nu13010183Izzo A., Massimino E., Riccardi G. et al. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients. 2021;13(1):183. DOI: 10.3390/nu13010183Liccini A., Malmstrom T.K. Frailty and sarcopenia as predictors of adverse health outcomes in persons with diabetes mellitus. J. Am. Med. Dir. Assoc. 2016;17(9):846–851. DOI: 10.1016/j.jamda.2016.07.007Liccini A., Malmstrom T.K. Frailty and sarcopenia as predictors of adverse health outcomes in persons with diabetes mellitus. J. Am. Med. Dir. Assoc. 2016;17(9):846–851. DOI: 10.1016/j.jamda.2016.07.007Kawada T. Mortality risk of sarcopenia in older subjects. J. Am. Med. Dir. Assoc. 2021;22(9):1883. DOI: 10.1016/j.jamda.2021.04.011.Kawada T. Mortality risk of sarcopenia in older subjects. J. Am. Med. Dir. Assoc. 2021;22(9):1883. DOI: 10.1016/j.jamda.2021.04.011.Xu J., Wan C.S., Ktoris K. et al. Sarcopenia is associated with mortality in adults: a systematic review and meta-analysis. Gerontology. 2022;68(4):361–376. DOI: 10.1159/000517099Xu J., Wan C.S., Ktoris K. et al. Sarcopenia is associated with mortality in adults: a systematic review and meta-analysis. Gerontology. 2022;68(4):361–376. DOI: 10.1159/000517099Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M., Boirie Y., Cederholm T., Landi F., Martin F.C., Michel J.P., Rolland Y., Schneider S.M., Topinkova E., Vandewoude M., Zamboni M. Sarcopenia: European consensus on defi nition and diagnosis - Report of the European working group on Sarcopenia in older people. Age Ageing. 2010;39:412–423. DOI: 10.1093/ageing/afq034Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M., Boirie Y., Cederholm T., Landi F., Martin F.C., Michel J.P., Rolland Y., Schneider S.M., Topinkova E., Vandewoude M., Zamboni M. Sarcopenia: European consensus on defi nition and diagnosis - Report of the European working group on Sarcopenia in older people. Age Ageing. 2010;39:412–423. DOI: 10.1093/ageing/afq034Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., Schneider S.M., Sieber C.C., Topinkova E., Vandewoude M., Visser M., Zamboni M. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2.Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., Schneider S.M., Sieber C.C., Topinkova E., Vandewoude M., Visser M., Zamboni M. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2.Аметов А.С., Пуговкина Я.В. Гомеостаз глюкозы и метаболическая гибкость у здоровых людей. Эндокринология: новости, мнения, обучение. 2020;9(4):12–22. DOI: 10.33029/2304-9529-2020-9-4-12-22Ametov A.S., Pugovkina Ya.V. Glucose homeostasis and metabolic fl exibility in healthy people. Endocrinology: news, opinions, training. 2020;9(4):12–22. (In Russian). DOI: 10.33029/2304-9529-2020-9-4-12-22Mesinovic J., Zengin A., De Courten B., Ebeling P.R. and Scott D. Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship. Diabetes Metab. Syndr. Obes. 2019;12:1057–1072. DOI: 10.2147/DMSO.S186600Mesinovic J., Zengin A., De Courten B., Ebeling P.R. and Scott D. Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship. Diabetes Metab. Syndr. Obes. 2019;12:1057–1072. DOI: 10.2147/DMSO.S186600Rizvi A.A., Rizzo M. Age-Related Changes in Insulin Resistance and Muscle Mass: Clinical Implications in Obese Older Adults. Medicina (Kaunas). 2024;60(10):1648. DOI: 10.3390/medicina60101648.Rizvi A.A., Rizzo M. Age-Related Changes in Insulin Resistance and Muscle Mass: Clinical Implications in Obese Older Adults. Medicina (Kaunas). 2024;60(10):1648. DOI: 10.3390/medicina60101648.Wu H., Liu M., Chi V.T.Q. et al. Handgrip strength is inversely associated with metabolic syndrome and its separate components in middle aged and older adults: a large-scale population-based study. Metabolism. 2019;93:61–67.Wu H., Liu M., Chi V.T.Q. et al. Handgrip strength is inversely associated with metabolic syndrome and its separate components in middle aged and older adults: a large-scale population-based study. Metabolism. 2019;93:61–67.Zamboni M., Gattazzo S., Rossi A.P. Myosteatosis: a relevant, yet poorly explored element of sarcopenia. Eur. Geriatr. Med. 2019;10(1):5–6. DOI: 10.1007/s41999-018-0134-3Zamboni M., Gattazzo S., Rossi A.P. Myosteatosis: a relevant, yet poorly explored element of sarcopenia. Eur. Geriatr. Med. 2019;10(1):5–6. DOI: 10.1007/s41999-018-0134-3Тополянская С.В. Жировая ткань и лептин при старении. Клиническая геронтология. 2020; 26 (7-8): 57-63. DOI: 10.26347/1607- 2499202007-08057-063.Topolyanskaya SV. Adipose tissue and adipokines in the elderly. Clin. Gerontol. 2020; 26 (7-8): 57-63. DOI: 10.26347/1607-2499202007-08057-063.Mitchell W.K., Williams J., Atherton P. et al. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012;3:260. DOI: 10.3389/fphys.2012.00260Mitchell W.K., Williams J., Atherton P. et al. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012;3:260. DOI: 10.3389/fphys.2012.00260Cretoiu D., Pavelescu L., Duica F., Radu M., Suciu N., Cretoiu S.M. Myofi bers. Adv. Exp. Med. Biol. 2018;1088:23–46. DOI: 10.1007/978-981-13-1435-3_2.Cretoiu D., Pavelescu L., Duica F., Radu M., Suciu N., Cretoiu S.M. Myofi bers. Adv. Exp. Med. Biol. 2018;1088:23–46. DOI: 10.1007/978-981-13-1435-3_2.Coelho-Junior H.J., Picca A., Calvani, R., Uchida M.C., Marzetti E. If my muscle could talk: Myokines as a biomarker of frailty. Exp. Gerontol. 2019;127:110715 DOI: 10.1016/j.exger.2019.110715Coelho-Junior H.J., Picca A., Calvani, R., Uchida M.C., Marzetti E. If my muscle could talk: Myokines as a biomarker of frailty. Exp. Gerontol. 2019;127:110715 DOI: 10.1016/j.exger.2019.110715Briana D.D., Malamitsi-Puchner A. Developmental origins of adult health and disease: The metabolic role of BDNF from early life to adulthood. Metabolism. 2018;81:45–51. DOI: 10.1016/j.metabol.2017.11.019Briana D.D., Malamitsi-Puchner A. Developmental origins of adult health and disease: The metabolic role of BDNF from early life to adulthood. Metabolism. 2018;81:45–51. DOI: 10.1016/j.metabol.2017.11.019Levy M.J.F., Boulle F., Steinbusch H.W., van den Hove D.L.A., Kenis G., Lanfumey L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology. 2018;235:2195–2220. DOI: 10.1007/s00213-018-4950-4Levy M.J.F., Boulle F., Steinbusch H.W., van den Hove D.L.A., Kenis G., Lanfumey L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology. 2018;235:2195–2220. DOI: 10.1007/s00213-018-4950-4Chen W., Wang L., You W., Shan T. Myokines mediate the cross talk between skeletal muscle and other organs. J. Cell. Physiol. 2021;236:2393–2412. DOI: 10.1002/jcp.30033:Chen W., Wang L., You W., Shan T. Myokines mediate the cross talk between skeletal muscle and other organs. J. Cell. Physiol. 2021;236:2393–2412. DOI: 10.1002/jcp.30033:Wacker M., Holick MF. Vitamin D-eff ects on skeletal and extraskeletal health and the need for supplementation. Nutrients. 2013;5(1):111–48. DOI: 10.3390/nu5010111Wacker M., Holick MF. Vitamin D-eff ects on skeletal and extraskeletal health and the need for supplementation. Nutrients. 2013;5(1):111–48. DOI: 10.3390/nu5010111Wintermeyer E., Ihle C., Ehnert S., Stöckle U., Ochs G., De Zwart P. et al. Crucial role of vitamin D in the musculoskeletal system. Nutrients. 2016;8(6):319. DOI: 10.3390/nu8060319Wintermeyer E., Ihle C., Ehnert S., Stöckle U., Ochs G., De Zwart P. et al. Crucial role of vitamin D in the musculoskeletal system. Nutrients. 2016;8(6):319. DOI: 10.3390/nu8060319Oshiro CE., Hillier TA., Edmonds G., Peterson M., Hill PL, Hampson S. Vitamin D defi ciency and insuffi ciency in Hawaii: levels and sources of serum vitamin D in older adults. Am. J. Hum. Biol. 2022;34(3):e23636. DOI: 10.1002/ajhb.23636Oshiro CE., Hillier TA., Edmonds G., Peterson M., Hill PL, Hampson S. Vitamin D defi ciency and insuffi ciency in Hawaii: levels and sources of serum vitamin D in older adults. Am. J. Hum. Biol. 2022;34(3):e23636. DOI: 10.1002/ajhb.23636Gallagher J.C. Vitamin D and aging. Endocr. Metab. Clin. 2013;42(2):319–32. DOI: 10.1016/j.ecl.2013.02.004.Gallagher J.C. Vitamin D and aging. Endocr. Metab. Clin. 2013;42(2):319–32. DOI: 10.1016/j.ecl.2013.02.004.Uchitomi R., Oyabu M., Kamei Y. Vitamin D and sarcopenia: potential of vitamin D supplementation in sarcopenia prevention and treatment. Nutrients. 2020;12(10):3189. DOI: 10.3390/nu12103189Uchitomi R., Oyabu M., Kamei Y. Vitamin D and sarcopenia: potential of vitamin D supplementation in sarcopenia prevention and treatment. Nutrients. 2020;12(10):3189. DOI: 10.3390/nu12103189Remelli F., Vitali A., Zurlo A. et al. Vitamin D defi ciency and sarcopenia in older persons. Nutrients. 2019;11(12):2861. DOI: 10.3390/nu11122861Remelli F., Vitali A., Zurlo A. et al. Vitamin D defi ciency and sarcopenia in older persons. Nutrients. 2019;11(12):2861. DOI: 10.3390/nu11122861Kalyani R.R., Metter E.J., Egan J. et al. Hyperglycemia predicts persistently lower muscle strength with aging. Diabetes Care. 2015;38(1):82–90. DOI: 10.2337/dc14-1166Kalyani R.R., Metter E.J., Egan J. et al. Hyperglycemia predicts persistently lower muscle strength with aging. Diabetes Care. 2015;38(1):82–90. DOI: 10.2337/dc14-1166Yaribeygi H., Farrokhi F.R., Butler A.E. et al. Insulin resistance: review of the underlying molecular mechanisms. J. Cell. Physiol. 2019;234(6):8152–8161. DOI: 10.1002/jcp.27603Yaribeygi H., Farrokhi F.R., Butler A.E. et al. Insulin resistance: review of the underlying molecular mechanisms. J. Cell. Physiol. 2019;234(6):8152–8161. DOI: 10.1002/jcp.27603Liu Z.J., Zhu C.F. Causal relationship between insulin resistance and sarcopenia. Diabetol. Metab. Syndr. 2023;15(1):46. DOI: 10.1186/s13098-023-01022-z.Liu Z.J., Zhu C.F. Causal relationship between insulin resistance and sarcopenia. Diabetol. Metab. Syndr. 2023;15(1):46. DOI: 10.1186/s13098-023-01022-z.Giha H.A., Alamin O.A.O., Sater M.S. Diabetic sarcopenia: metabolic and molecular appraisal. Acta Diabetol. 2022;59(8):989– 1000. DOI: 10.1007/s00592-022-01883-2Giha H.A., Alamin O.A.O., Sater M.S. Diabetic sarcopenia: metabolic and molecular appraisal. Acta Diabetol. 2022;59(8):989– 1000. DOI: 10.1007/s00592-022-01883-2Goossens G.H., Blaak E.E., Theunissen R. et al. Expression of NLRP3 infl ammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol. Immunol. 2012;50(3):142–149. DOI: 10.1016/j.molimm.2012.01.005Goossens G.H., Blaak E.E., Theunissen R. et al. Expression of NLRP3 infl ammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol. Immunol. 2012;50(3):142–149. DOI: 10.1016/j.molimm.2012.01.005Mcbride M.J., Foley K.P., D’souza D.M. et al. The NLRP3 infl ammasome contributes to sarcopenia and lower muscle glycolytic potential in old mice. Am. J. Physiol. Endocrinol. Metab. 2017;313(2):E222– E232. DOI: 10.1152/ajpendo.00060.2017Mcbride M.J., Foley K.P., D’souza D.M. et al. The NLRP3 infl ammasome contributes to sarcopenia and lower muscle glycolytic potential in old mice. Am. J. Physiol. Endocrinol. Metab. 2017;313(2):E222– E232. DOI: 10.1152/ajpendo.00060.2017Shimizu N. et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell. Metab. 2011;13(2):170–182. DOI: 10.1016/j.cmet.2011.01.001.Shimizu N. et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell. Metab. 2011;13(2):170–182. DOI: 10.1016/j.cmet.2011.01.001.Hirata Y., Nomura K., Senga Y., Okada Y., Kobayashi K., Okamoto S., Minokoshi Y., Imamura M., Takeda S., Hosooka T., Ogawa W. Hyperglycemia induces skeletal muscle atrophy via a WWP1/ KLF15 axis. JCI Insight. 2019;4(4):e124952. DOI: 10.1172/jci.insight.124952.Hirata Y., Nomura K., Senga Y., Okada Y., Kobayashi K., Okamoto S., Minokoshi Y., Imamura M., Takeda S., Hosooka T., Ogawa W. Hyperglycemia induces skeletal muscle atrophy via a WWP1/ KLF15 axis. JCI Insight. 2019;4(4):e124952. DOI: 10.1172/jci.insight.124952.Dasarathy S., Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J. Hepatol. 2016;65(6):1232–1244. DOI: 10.1016/j.jhep.2016.07.040Dasarathy S., Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J. Hepatol. 2016;65(6):1232–1244. DOI: 10.1016/j.jhep.2016.07.040Yoshida T., Delafontaine P. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020;9(9):1970. DOI: 10.3390/cells9091970Yoshida T., Delafontaine P. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020;9(9):1970. DOI: 10.3390/cells9091970Bassil M.S., Gougeon R. Muscle protein anabolism in type 2 diabetes. Curr. Opin. Clin. Nutr. Metab. Care. 2013;16(1):83–88. DOI: 10.1097/MCO.0b013e32835a88eeBassil M.S., Gougeon R. Muscle protein anabolism in type 2 diabetes. Curr. Opin. Clin. Nutr. Metab. Care. 2013;16(1):83–88. DOI: 10.1097/MCO.0b013e32835a88eeKalyani R.R., Corriere M., Ferrucci L. Age-related and diseaserelated muscle loss: the eff ect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014;2(10):819–829. DOI: 10.1016/S2213-8587(14)70034-8Kalyani R.R., Corriere M., Ferrucci L. Age-related and diseaserelated muscle loss: the eff ect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014;2(10):819–829. DOI: 10.1016/S2213-8587(14)70034-8Qiu J., Thapaliya S., Runkana A. et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism. Proc. Natl. Acad. Sci. USA. 2013;110(45):18162–18167. DOI: 10.1073/pnas.1317049110Qiu J., Thapaliya S., Runkana A. et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism. Proc. Natl. Acad. Sci. USA. 2013;110(45):18162–18167. DOI: 10.1073/pnas.1317049110Wang X.H., Mitch W.E. Mechanisms of muscle wasting in chronic kidney disease. Nat. Rev. Nephrol. 2014;10(9):504–516. DOI: 10.1038/nrneph.2014.112Wang X.H., Mitch W.E. Mechanisms of muscle wasting in chronic kidney disease. Nat. Rev. Nephrol. 2014;10(9):504–516. DOI: 10.1038/nrneph.2014.112Bataille S., Chauveau P., Fouque D. et al. Myostatin and muscle atrophy during chronic kidney disease. Nephrol. Dial. Transplant. 2021;36(11):1986–1993. DOI: 10.1093/ndt/gfaa129Bataille S., Chauveau P., Fouque D. et al. Myostatin and muscle atrophy during chronic kidney disease. Nephrol. Dial. Transplant. 2021;36(11):1986–1993. DOI: 10.1093/ndt/gfaa129Baczek J., Silkiewicz M., Wojszel Z.B. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. Nutrients. 2020;12(8):2401. DOI: 10.3390/nu12082401Baczek J., Silkiewicz M., Wojszel Z.B. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. Nutrients. 2020;12(8):2401. DOI: 10.3390/nu12082401Donath M.Y., Shoelson S.E. Type 2 diabetes as an infl ammatory disease. Nat. Rev. Immunol. 2011;11(2):98–107. DOI: 10.1038/nri2925Donath M.Y., Shoelson S.E. Type 2 diabetes as an infl ammatory disease. Nat. Rev. Immunol. 2011;11(2):98–107. DOI: 10.1038/nri2925Perry B.D., Caldow M.K., Brennan-Speranza T.C. et al. Muscle atrophy in patients with type 2 diabetes mellitus: roles of infl ammatory pathways, physical activity and exercise. Exerc. Immunol. Rev. 2016;22:94–109 PMID: 26859514; PMCID: PMC5545118Perry B.D., Caldow M.K., Brennan-Speranza T.C. et al. Muscle atrophy in patients with type 2 diabetes mellitus: roles of infl ammatory pathways, physical activity and exercise. Exerc. Immunol. Rev. 2016;22:94–109 PMID: 26859514; PMCID: PMC5545118Zhang X., Li H., He M. et al. Immune system and sarcopenia: presented relationship and future perspective. Exp. Gerontol. 2022;164:111823. DOI: 10.1016/j.exger.2022.111823Zhang X., Li H., He M. et al. Immune system and sarcopenia: presented relationship and future perspective. Exp. Gerontol. 2022;164:111823. DOI: 10.1016/j.exger.2022.111823Goyal R., Faizy A.F., Siddiqui S.S. et al. Evaluation of TNF-alpha and IL-6 levels in obese and non-obese diabetics: pre- and postinsulin eff ects. N. Am. J. Med. Sci. 2012;4(4):180–184. DOI: 10.4103/1947-2714.94944Goyal R., Faizy A.F., Siddiqui S.S. et al. Evaluation of TNF-alpha and IL-6 levels in obese and non-obese diabetics: pre- and postinsulin eff ects. N. Am. J. Med. Sci. 2012;4(4):180–184. DOI: 10.4103/1947-2714.94944Omura T., Araki A. Skeletal muscle as a treatment target for older adults with diabetes mellitus: the importance of a multimodal intervention based on functional category. Geriatr Gerontol. Int. 2022;22(2):110–120. DOI: 10.1111/ggi.14339Omura T., Araki A. Skeletal muscle as a treatment target for older adults with diabetes mellitus: the importance of a multimodal intervention based on functional category. Geriatr Gerontol. Int. 2022;22(2):110–120. DOI: 10.1111/ggi.14339Bowen T.S., Schuler G., Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachexia Sarcopenia Muscle. 2015;6(3):197– 207. DOI: 10.1002/jcsm.12043Bowen T.S., Schuler G., Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachexia Sarcopenia Muscle. 2015;6(3):197– 207. DOI: 10.1002/jcsm.12043Hyatt H.W., Powers S.K. The role of calpains in skeletal muscle remodeling with exercise and inactivity-induced atrophy. Int. J. Sports Med. 2020;41(14):994–1008. DOI: 10.1055/a-1199-7662Hyatt H.W., Powers S.K. The role of calpains in skeletal muscle remodeling with exercise and inactivity-induced atrophy. Int. J. Sports Med. 2020;41(14):994–1008. DOI: 10.1055/a-1199-7662Huang J., Zhu X. The molecular mechanisms of calpains action on skeletal muscle atrophy. Physiol. Res. 2016;65(4):547–560. DOI: 10.33549/physiolres.933087Huang J., Zhu X. The molecular mechanisms of calpains action on skeletal muscle atrophy. Physiol. Res. 2016;65(4):547–560. DOI: 10.33549/physiolres.933087Suzuki A., Yabu A., Nakamura H. Advanced glycation end products in musculoskeletal system and disorders. Methods. 2022;203:179– 186. DOI: 10.1016/j.ymeth.2020.09.012Suzuki A., Yabu A., Nakamura H. Advanced glycation end products in musculoskeletal system and disorders. Methods. 2022;203:179– 186. DOI: 10.1016/j.ymeth.2020.09.012Forbes J.M., Sourris K.C., De Courten M.P. et al. Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects. Amino Acids. 2014;46(2):321–326. DOI: 10.1007/s00726-013-1542-9Forbes J.M., Sourris K.C., De Courten M.P. et al. Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects. Amino Acids. 2014;46(2):321–326. DOI: 10.1007/s00726-013-1542-9Cleasby M.E., Jamieson P.M. Atherton P.J. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J. Endocrinol. 2016;229(2):R67–81. DOI: 10.1530/JOE-15-0533Cleasby M.E., Jamieson P.M. Atherton P.J. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J. Endocrinol. 2016;229(2):R67–81. DOI: 10.1530/JOE-15-0533Jimenez-Gutierrez G.E., Martínez-Gómez L.E., Martínez-Armenta C. et al. Molecular mechanisms of infl ammation in sarcopenia: diagnosis and therapeutic update. Cells. 2022;11(15):2359. DOI: 10.3390/cells11152359Jimenez-Gutierrez G.E., Martínez-Gómez L.E., Martínez-Armenta C. et al. Molecular mechanisms of infl ammation in sarcopenia: diagnosis and therapeutic update. Cells. 2022;11(15):2359. DOI: 10.3390/cells11152359Csapo R., Malis V., Sinha U. et al. Age-associated diff erences in triceps surae muscle composition and strength - an MRI-based crosssectional comparison of contractile, adipose and connective tissue. BMC Musculoskelet Disord. 2014;15:209. DOI: 10.1186/1471-2474-15-209.Csapo R., Malis V., Sinha U. et al. Age-associated diff erences in triceps surae muscle composition and strength - an MRI-based crosssectional comparison of contractile, adipose and connective tissue. BMC Musculoskelet Disord. 2014;15:209. DOI: 10.1186/1471-2474-15-209.

The authors declare that there are no conflicts of interest present.